Neoadjuvant Immunotherapy for early stage melanoma shows positive results


Immunotherapy before surgery for patients with metastatic melanoma appears to be especially successful. Fifty-nine percent of patients responds so well to this therapy that adjuvant treatment is no longer needed, according to the results of the NADINA study that were published today.

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.